| INTRODUCTION
Liver transplantation is the treatment of choice for patients with end-stage liver disease. In Western countries, deceased-donor procedures are standard, 1 with relatively rare use of living-donor grafts. 2, 3 In some regions such as East Asia, however, living-donor procedures account for more than 90% of liver transplants. 4, 5 Five-year survival rates of over 75% have been widely achieved after living-donor liver transplantation, [6] [7] [8] similar to rates achieved with deceased-donor transplantation.
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Calcineurin inhibitors (CNIs), although a mainstay of immunosuppression after liver transplantation, are associated with long-term complications such as nephrotoxicity 10, 11 and increased risk for hepatocellular carcinoma (HCC) recurrence. 12 This has prompted interest in strategies to minimize chronic CNI exposure, 13 for example through use of the mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressant. Everolimus is the only mTOR inhibitor approved worldwide for use in liver transplantation. mTOR inhibition can facilitate reduced-exposure CNI therapy, an approach that may optimize the balance between long-term efficacy and safety concerns. In the pivotal H2304 trial, which compared everolimus plus reduced-exposure tacrolimus versus standard tacrolimus immunosuppression in deceased donor liver transplants, renal function was significantly improved with the everolimus-based regimen. 14, 15 The use of mTOR inhibition has not been reported in the setting of living-donor transplantation.
We describe here the 12-month results of the ongoing randomized study (H2307) in which living-donor liver transplant recipients were randomized early posttransplant to everolimus with reduced tacrolimus or to standard tacrolimus therapy. The primary objective is to demonstrate comparable efficacy between the two regimens at 12 months posttransplant based on a non-inferiority analysis. The design of the study was similar to the H2304 trial in deceased-donor liver transplant recipients, but the current study population of livingdonor recipients was primarily recruited in Asia with a higher proportion of patients transplanted due to HCC and a lower mean model for end-stage liver disease (MELD) score.
| METHODS

| Study design and conduct
The H2307 trial is an ongoing 24-month Phase III multicenter, parallel-group, open-label study in which living-donor liver transplant patients receiving tacrolimus-based immunosuppression were randomized at 30 ± 5 days posttransplant to everolimus plus reduced tacrolimus (EVR + rTAC) or to continue standard tacrolimus therapy (standard TAC). Eligibility was assessed and informed consent was obtained during the screening period, which started prior to liver transplantation and ended with successful completion of the transplant procedure.
Recruitment of patients was carried out at 38 liver transplant centers in Asia, North America, Europe, and elsewhere (see Appendix).
The first patient first visit took place in September 2013 and the final 12-month study visit in October 2016. The study is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice following approval by the institutional review board at each center. Table S1 .
| Study population
| Randomization and study medication
During the run-in phase prior to randomization, all patients received tacrolimus (target trough concentration 5-15 ng/mL), and steroids according to local practice. Use of basiliximab induction was permitted (with use to be consistent across all patients at a given center) and mycophenolic acid (MPA) could be administered according to center practice. Randomization (1:1 ratio) was performed centrally by an Interactive Response Technology system, with stratification based on pre-transplant HCC status (positive/negative).
Patients randomized to the everolimus group received an initial everolimus dose of 2.0 mg/day, adjusted to target a trough concentration of 3-8 ng/mL throughout the study, and the tacrolimus target concentration was reduced to 3-5 ng/mL. In the standard TAC group, the target tacrolimus trough concentration was reduced to 8-12 ng/mL from randomization until month 4, and 6-10 ng/mL thereafter.
In both groups, MPA (if given) was to be discontinued at the time of randomization. Steroid therapy is optional in both treatment groups after randomization, as per local practice.
All patients positive for hepatitis B virus (HBV) receive prophylaxis throughout the study to prevent recurrence, as per local practice. Cytomegalovirus (CMV) prophylaxis or preemptive monitoring for CMV is administered according to local practice, applied uniformly for all subjects at a given center. Pneumocystis carinii pneumonia (PCP)
prophylaxis was mandatory for at least three months posttransplant, administered as per local practice.
| Study endpoints
The primary endpoint is a composite efficacy failure endpoint of treated biopsy-proven acute rejection (tBPAR > rejection activity index [RAI] score 3), graft loss, or death at month 12 posttransplant.
The key secondary endpoint is change in eGFR (MDRD-4 formula
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) from randomization to month 12 posttransplant. Other secondary endpoints are listed in Table S2 .
At centers where it is local practice to assess HCC recurrence by month 6 using CT or MRI scans, liver volume was assessed based on the first posttransplant scan performed at the month 2 study visit or subsequently. Scans were read centrally for liver volume assessment and compared to the initial liver volume at time of transplant.
| Statistical analysis
Due to slower than expected recruitment, the initial sample size of 470 patients was reduced to 280 subjects, with an increase in the one-sided α error rate from 2.5% to 5%. A sample size of 280 patients (140 in The primary endpoint (tBPAR, graft loss or death at month 12 posttransplant) was assessed using the two-sided 90% Z-test based on confidence intervals (CIs) for the between-treatment difference.
The proportion of patients with efficacy failure in each treatment group was estimated by the Kaplan-Meier product-limit formula and standard error (SE) by Greenwood's formula. Other statistical methods are summarized in Table S2 .
Efficacy and renal endpoints are analyzed in the intention-to-treat (ITT) population, comprising all randomized patients. A supportive analysis of the key secondary endpoint was carried out based on the subpopulation of patients who remained on study drug. Safety evaluations are based on all randomized patients who received ≥1 dose of study medication (the safety population).
| RESULTS
| Patient population
In total, 448/494 screened patients (90.7%) met the eligibility criteria and were enrolled in the study (Figure 1 
| Efficacy
The EVR+rTAC group was non-inferior to the TAC Control group for the primary endpoint (tBPAR, graft loss or death). The endpoint oc- log rank P = .805). Thus, the pre-defined criterion for non-inferiority that the upper limit of the CI range for the difference be <12% was met. When the incidence of the primary endpoint was assessed within pre-defined subgroups (i.e. according to use of basiliximab induction, recipient age, gender, pre-transplant HCC and hepatitis C virus (HCV) status, and MELD score) no significant differences between treatment groups were observed (Table S3) .
tBPAR occurred once in three EVR+rTAC patients (2 borderline, 1 mild) and once in five TAC Control patients (1 borderline, 1 mild, 2 moderate and 1 severe) ( Figure 3B ). The incidence of BPAR, treated acute rejection and acute rejection were similar between treatment groups ( Table 2) . Four patients died in the EVR+rTAC group, due to multiple gastrointestinal bleeding/fungal sepsis, septic shock, respiratory/cardiac failure and pneumonia/septic shock, and three patients died in the TAC Control arm (metastatic HCC, lower respiratory tract infection/altered state of consciousness, lower respiratory tract infection and pulmonary infarction). There were no graft losses reported in either treatment group by month 12.
| Renal function
Observed mean eGFR was significantly higher in the EVR+rTAC group versus the TAC Control group until month 6, after which the 
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. Accordingly, the lower limit of the 90% CI range was greater than the pre-specified noninferiority margin of −6 mL/min/1.73 m 2 (P < .001 for non-inferiority)
i.e. EVR+rTAC was non-inferior to the TAC Control group at month 12.
Similar results were shown when the analysis was repeated based on GFR estimated by the MDRD-6, Cockcroft-Gault or Hoek formulae (Table S4) . When tested for superiority, the between-group difference in eGFR (MDRD-4) was not significant (P = .108).
The supportive analysis of the key secondary endpoint in the subpopulation of patients who remained on study drug also showed non-inferiority for EVR+rTAC, consistent with the primary analysis: the mean (SE) change from randomization was −8.0 (1.9) mL/min/1.73 m 9.6) (P = .046).
When assessed in pre-specified subgroups, the between-group difference in change in observed mean eGFR was similar in both treatment groups (Table S5) .
At month 12, the proportion of patients in the EVR+rTAC group versus the TAC Control group with urine protein:creatinine in the sub-nephrotic range (300 to <1000 mg/g) was 11.6% (15/129) versus 0% (0/131); the incidence of urine protein:creatinine ≥3000 mg/g was 1.6% (2/129) versus 0% (0/131), respectively. Proteinuria in the range 1.0 to <3.0 g/24 h only occurred in the EVR+rTAC group (7.8%; 10/129). Two EVR+rTAC patients (2/129; 1.6%), and no TAC Control patients, had proteinuria ≥3.0 g/24 h.
During the study, three EVR + rTAC patients and one TAC Control patient required dialysis. Among the 94 patients for whom data on Milan criteria were provided, the majority (40/44 EVR+rTAC; 43/50 TAC Controls) were within Milan criteria. Tumor sizes were slightly larger in the TAC Control arm at baseline (Table 3) .
| HCC recurrence
T A B L E 2 Efficacy endpoints (ITT population)
F I G U R E 4 Estimated GFR (MDRD-4). Values are shown as mean (SD
At 12 months, there were no cases of HCC recurrence in the EVR + rTAC group. In the TAC Control group, 5 of 62 patients with HCC at the time of transplant experienced recurrence (0% for EVRrTAC vs. 8.1% for TAC Control). The characteristics of HCC in these five patients are summarized in Table S6 . All five patients were outside Milan criteria at the time of study entry. Four of the patients had HCC as the primary indication for transplantation; in the fifth case, HCC was diagnosed incidentally on the explanted liver.
Recurrence was reported on days 145,197, 297, 360, and 367 posttransplant. All five patients had recurrence at extrahepatic locations (four lungs, one bone) and one patient had recurrence at both hepatic and extrahepatic locations. One case was fatal. No case was considered by the investigator to be related to tacrolimus. In two patients, everolimus was initiated and tacrolimus was given as per local standard of care. Serious adverse events or infections occurred in 49.3% of EVR + rTAC patients (70/142), most frequently HCV recurrence (n = 5), abdominal pain (n = 7) and bile duct stenosis (n = 9) and in 43.3% of TAC Control patients (61/141), the most frequent of which were HCV recurrence (n = 3) and bile duct stenosis (n = 6). Adverse events or infections (and serious adverse events or infections) with a suspected relation to study drug were more frequent with EVR + rTAC than in the TAC Control group (Table 4) .
| Safety
Rates of study discontinuation due to adverse events or infection Liver regeneration was assessed in a subset of patients (Table 5) . EVR+rTAC group versus 9.2% (13/141) in the TAC Control group, the most frequent of which were anastomotic strictures (14 EVR+rTAC, 9
TAC Control) and bile leaks (6 EVR+rTAC, 13 TAC Control).
Laboratory results at month 12 showed significantly higher mean levels of total cholesterol, LDL-cholesterol and triglycerides with EVR+rTAC versus the TAC Control group (Table S8) . Use of lipidlowering therapy was also higher in the EVR+rTAC group (35.9%
[51/142] versus 8.5% [12/141] ). Mean total bilirubin was lower in the EVR+rTAC group versus the TAC Control arm (Table S9) The H2304 study, which used a similar protocol in deceaseddonor liver transplant patients, showed superior renal function using EVR + rTAC. 14 In the H2304 study, MELD scores were higher on entry compared to the current trial, reflecting the shortage of deceased organ donors and long waiting times for transplantation. 18 The mean eGFR at baseline in the current study population was 90 mL/ min/1.73 m 2 compared to ~80 mL/min/1.73 m 2 in the H2304 study, which may have affected the potential for improvement under a reduced CNI regimen. Another confounding factor in the present study was the observation that tacrolimus exposure exceeded the protocolspecified upper limits in everolimus-treated patients for the first six months of the study, while mean concentration remained close to the lower limit in the TAC Control group over the same period. Conversely, the higher-than-expected tacrolimus exposure may have contributed to the absence of moderate or severe acute rejection in the EVR+rTAC group. By month 12, only 2% of EVR+rTAC patients had experienced tBPAR, and two of the three episodes which occurred were of borderline severity. In future trials, more rigorous adherence to specified tacrolimus target levels may allow for lower exposure of tacrolimus with a greater benefit for renal function without compromising efficacy.
Subnephrotic proteinuria occurred only in the EVR+rTAC group, consistent with evidence from kidney transplantation that proteinuria is more frequent under mTOR inhibitors than CNI therapy. 19 Proteinuria in the nephritic range was seen only in the EVR+rTAC group, but was rare (1.6%) and proteinuria led to study drug discontinuation in only three patients. Nevertheless, this reinforces the need for regular monitoring of urinary protein and avoidance of mTOR therapy in patients with proteinuria ≥1.0 g/24 h, as in the current study and elsewhere. T A B L E 5 Liver regeneration in a subset of patients (ITT population) particularly in low-risk patients. 35 In the current cohort, HCC recurrence occurred in no EVR+rTAC patients and in 8.1% of TAC Control patients. It should be noted that at baseline the mean alpha fetoprotein level was higher, and maximum tumor size was larger, in the TAC Control group. However, in four of the five cases of HCC recurrence, the patients had relatively low alpha fetoprotein levels (≤501 μg/L).
Study data on HCC recurrence rates at the end of this 24-month study will be of interest.
An important finding was the observation that liver regeneration in patients treated with everolimus was equivalent to patients receiving standard tacrolimus-based immunosuppression. This is highly relevant since a concern about the use of mTOR inhibition in patients receiving small liver grafts would be inhibition of regeneration, leading to small-for-size graft syndrome. None of the patients in the everolimus arm developed clinical or biochemical signs of small-for-size graft syndrome. Although only a small subset of patients was studied, the data is encouraging and suggests that the introduction of everolimus one month after transplantation does not affect the regeneration of the graft.
Notably, the rate of study drug discontinuation due to adverse events was similar between treatment groups, and low in both arms. This is a highly encouraging finding since discontinuation of everolimus due to adverse events when given in combination with reduced-CNI was more common than under standard CNI in the H2304 trial 14 and in a large randomized trial of kidney transplant recipients. 36 It is tempting to speculate that growing experience with mTOR inhibitors is leading to improved confidence in managing associated adverse events, including graft rejection, but this cannot be confirmed. Early doses of everolimus were similar in the current trial and H2304, but by month 12 the mean everolimus dose was slightly lower here (2.6 mg/ day) than in H2304 (3.1 ng/mL), possibly suggesting greater use of dose reductions instead of discontinuation.
There were a number of adverse events which occurred more frequently in the EVR+rTAC group than in the TAC Control arm, many of which (e.g. dyslipidemia, mouth ulceration and hematological effects)
are known side effects of mTOR inhibitor-based therapy. [37] [38] [39] Rates of adverse events and serious adverse events with a suspected relation to study drug were more frequent in the EVR+rTAC group. However, in the TAC Control arm 9.5% of patients had experienced serious adverse events which started during the run-in period and were therefore not included in the post-randomization rates of adverse events. Rates of infections and serious infections were slightly higher under EVR+rTAC, possibly related to the unexpectedly higher tacrolimus exposure levels, but viral infections (including HCV, CMV and EBV) showed no difference. The rate of wound healing complications was similar in both groups, although it was notable that incisional hernias were seen only in the EVR+rTAC group.
The study employed a randomized design, in a large population of living-donor living transplant recipients at multiple centers. Data on HCC at baseline and HCC recurrence were rigorously collected, and patients were stratified at randomization according to baseline HCC status. The non-inferiority margin of 12%, based upon published studies from the 1990s and 2000s, may have been overly wide.
Given the very small between-group difference (0.7%) this would not have been expected to affect the conclusion of non-inferiority in the EVR+rTAC group, but the low event rate compared to the a priori assumption affects the Type I error of the study in the context of this non-inferiority design, potentially biasing towards the alternative hypothesis of non-inferiority. Certain planned comparative analyses (e.g. time to HCC recurrence) could not be performed at month 12 since there were no HCC recurrent events in the EVR+rTAC Group.
It should also be noted that more than three-quarters of the patients were recruited in Asia, and the results may not be applicable in other regions. For example, there was a low body mass index (~23 kg/m 2 ) and in other countries with higher body weights the metabolic effects of an everolimus-based regimen, such as dyslipidemia, may be more pronounced.
In conclusion, EVR+rTAC from one month after living-donor liver transplantation is non-inferior to standard tacrolimus therapy in terms of both efficacy and renal function at 12 months posttransplant.
Tolerability was similar between groups. Importantly, early HCC recurrence may be less frequent with EVR+rTAC in this setting, a possibility that merits further investigation. The trial continues to follow patients to two years after transplantation to gather longer-term data.
